ArticleCancer immunology, immunotherapy : CII2020
Expression of the immune checkpoint VISTA in breast cancer.
Article in Cancer immunology, immunotherapy : CII, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it, 93 citations in OpenAlex.
- Identification and validation of TNFRSF4 as a high-profile biomarker for prognosis and immunomodulation in endometrial carcinoma.BMC cancer · 2022Pooled it
- Plant extracts and phytochemicals in canine and feline mammary cancer models: current evidence and comparative perspectives.Veterinary research communications · 2026Review
- VISTA: bridging gaps in cancer immunotherapy.Discover oncology · 2026Review
- An immune checkpoint-based score is a prognostic marker in retrospective cohort study of patients with gastric cancer.Translational cancer research · 2025Article
- VISTA: An Emerging Immune Checkpoint With Clinical Relevance Across Diverse Malignancies.Immune network · 2025Review
- Targeted destruction of VISTA boosts anti-tumor immunotherapy.Cell research · 2025Article
- The role of immune checkpoints in modulating cancer stem cells anti-tumor immune responses: implications and perspectives in cancer therapy.Journal of experimental & clinical cancer research : CR · 2025Review
- Dual membrane receptor degradation via folate receptor targeting chimera.Nature communications · 2025Article
- Exploring IgSF11 as a potential immune checkpoint and immunotherapeutic target in breast cancer.Cancer immunology, immunotherapy : CII · 2025Article
- Negative Immune Checkpoint Inhibitors.Pharmaceutics · 2025Review
- Expression of VISTA on T cells in patients with cancer colon.Journal of the Egyptian National Cancer Institute · 2025Article
- Radiogenomic analysis of clinical and ultrasonic characteristics in correlation to immune-related genes in breast cancer.Scientific reports · 2025Article
- Immune evasion and resistance in breast cancer.American journal of cancer research · 2025Review
- Therapeutic targeting of tumour-associated macrophage receptors.Immunotherapy advances · 2025Review
- Biomarkers to predict the benefits of immune‑checkpoint blockade‑based therapy in patients with malignant peritoneal mesothelioma (Review).Oncology letters · 2024Review
- VISTA-mediated immune evasion in cancer.Experimental & molecular medicine · 2024Review
- Expression and Prognostic Significance of LAG-3, TIGIT, VISTA, and IDO1 in Endometrial Serous Carcinoma.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2024Article
- Immunotherapy for Metastatic Triple Negative Breast Cancer: Current Paradigm and Future Approaches.Current treatment options in oncology · 2023Review
- Review
- Incorporating Molecular Classification When Stratifying the Survival Risk of Patients with High-Grade Endometrial Carcinomas.Journal of clinical medicine · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
V-domain Ig suppressor of T cell activation (VISTA) is a novel immune checkpoint that is an emerging target for cancer immunotherapy. This study aimed to investigate the expression of VISTA and its association with clinicopathologic parameters as well as with the key immune markers including programmed cell death-1 (PD-1) and PD-1 ligand-1 (PD-L1) in invasive ductal carcinoma (IDC) of the breast [corrected]. Immunohistochemistry was used to detect VISTA, PD-1, PD-L1, and CD8 in tissue microarrays from 919 patients with IDC (N = 341 in the exploratory cohort and = 578 in the validation cohort). VISTA was expressed on the immune cells of 29.1% (267/919) of the samples and on the tumor cells of 8.2% (75/919). VISTA was more frequently expressed in samples that were estrogen receptor-negative, progesterone receptor-negative, human epidermal growth factor receptor 2-positive, poorly differentiated, human epidermal growth factor receptor 2-enriched, and consisting of basal-like tumors. VISTA on immune cells correlated with PD-1, PD-L1, stromal CD8, and tumor-infiltrating lymphocyte expression and was an independent prognostic factor for improved relapse-free and disease-specific survival in patients with estrogen receptor-negative, progesterone receptor-negative, and basal-like IDC. These findings support therapeutic strategies that modulate VISTA expression, perhaps in combination with PD-1/PD-L1 blockade, in human breast cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.